DWTX.US Dogwood Therapeutics, Inc.

Healthcare Biotechnology USA Stocks
1.11 USD
Close of Nov 14, 2026
0.9010 7.04
Market cap
USD 42.4M
P/E
0.1x
P/B
0.66x
ROE
-44.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is DWTX.US undervalued?

Graham number

The Graham number of Dogwood Therapeutics, Inc. cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Dogwood Therapeutics, Inc. fundamental analysis

No fundamental analysis for Dogwood Therapeutics, Inc. yet.

Dogwood Therapeutics, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical …

Full company profile